Pfizer (NYSE:PFE) Hits New 1-Year High – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $29.27 and last traded at $29.1190, with a volume of 7,820,373 shares. The stock had previously closed at $28.37.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pipeline momentum: Pfizer plans to present data from more than 50 research abstracts at IDWeek 2026, including Phase 3 results for its Lyme vaccine candidate, next-generation pneumococcal vaccine programs, and updates involving RSV, COVID-19 and other infectious diseases. These potential catalysts are helping reinforce confidence in Pfizer’s vaccine pipeline. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: New drug-development collaboration: Pfizer entered a research collaboration and licensing agreement with Enodia Therapeutics focused on Sec61-targeting small molecules. The deal could expand Pfizer’s external innovation and long-term pipeline, although financial and clinical outcomes remain uncertain. Pfizer partners with Enodia Therapeutics in $500m drug deal
• Positive Sentiment: Income appeal: Recent investor commentary highlights Pfizer’s dividend yield of roughly 6.3%, making PFE attractive to income-focused investors seeking alternatives to bonds and other high-yield stocks. Pfizer also declared a quarterly dividend of $0.43 per share. 2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends
• Positive Sentiment: Sector rotation and technical interest: Buying has rotated from technology and artificial-intelligence stocks toward healthcare, lifting Pfizer alongside other drugmakers. Pfizer also received favorable visibility from CNBC’s “Final Trades,” while call-option activity was unusually elevated, suggesting increased near-term speculative interest. Moderna Rallies as Money Rotates Into Healthcare
• Neutral Sentiment: Analyst valuation remains mixed: The reported broker consensus price target is $28.72, below the current trading level, which may limit upside unless analysts raise estimates to reflect pipeline progress. Pfizer’s latest quarterly results beat expectations, and full-year 2026 EPS guidance is $2.80-$3.00.
• Negative Sentiment: Dividend and execution risks: Pfizer’s high yield reflects investor concerns about post-COVID revenue declines, future product growth and the sustainability of its payout. Pipeline programs and collaborations still face clinical, regulatory and commercial risks, particularly as the stock approaches its recent high.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Scotiabank raised their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday. JPMorgan Chase & Co. upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Cantor Fitzgerald increased their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Finally, HSBC increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.72.

Pfizer Price Performance

The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average price is $27.94 and its 200 day moving average price is $26.55. The stock has a market cap of $167.94 billion, a PE ratio of 9.58, a P/E/G ratio of 1.98 and a beta of 0.32.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Trading of Pfizer

Large investors have recently added to or reduced their stakes in the company. Community Financial Services Group LLC lifted its holdings in shares of Pfizer by 5.0% in the 3rd quarter. Community Financial Services Group LLC now owns 15,775 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 752 shares during the last quarter. Fortitude Family Office LLC increased its stake in Pfizer by 72.8% during the third quarter. Fortitude Family Office LLC now owns 2,148 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 905 shares during the last quarter. Perpetual Ltd raised its position in Pfizer by 11.8% during the third quarter. Perpetual Ltd now owns 150,513 shares of the biopharmaceutical company’s stock valued at $4,293,000 after purchasing an additional 15,937 shares during the period. Scott Capital Advisors LLC purchased a new stake in Pfizer during the third quarter valued at approximately $405,000. Finally, HF Advisory Group LLC raised its position in Pfizer by 7.8% during the third quarter. HF Advisory Group LLC now owns 110,318 shares of the biopharmaceutical company’s stock valued at $3,146,000 after purchasing an additional 7,940 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.